The PAV trial: does lactobacillus prevent post-antibiotic vulvovaginal candidiasis? Protocol of a randomised controlled trial [ISRCTN24141277].
BACKGROUND
Complementary and alternative medicines are used by many consumers, and increasingly are being incorporated into the general practitioner's armamentarium. Despite widespread usage, the evidence base for most complementary therapies is weak or non-existent. Post-antibiotic vulvovaginitis is a common problem in general practice, for which complementary therapies are often used. A recent study in Melbourne, Australia, found that 40% of women with a past history of vulvovaginitis had used probiotic Lactobacillus species to prevent or treat post-antibiotic vulvovaginitis. There is no evidence that this therapy is effective. This study aims to test whether oral or vaginal lactobacillus is effective in the prevention of post-antibiotic vulvovaginitis.


METHODS
A randomised placebo-controlled blinded 2 x 2 factorial design is being used. General practitioners or pharmacists approach non-pregnant women, aged 18-50 years, who present with a non-genital infection requiring a short course of oral antibiotics, to participate in the study. Participants are randomised in a four group factorial design either to oral lactobacillus powder or placebo and either vaginal lactobacillus pessaries or placebo. These interventions are taken while on antibiotics and for four days afterwards or until symptoms of vaginitis develop. Women self collect a vaginal swab for culture of Candida species and complete a survey at baseline and again four days after completing their study medications. The sample size (a total of 496--124 in each factorial group) is calculated to identify a reduction of half in post-antibiotic vulvovaginitis from 23%, while allowing for a 25% drop-out. An independent Data Monitoring Committee is supervising the trial. Analysis will be intention-to-treat, with two pre-specified main comparisons: (i) oral lactobacillus versus placebo and (ii) vaginal lactobacillus versus placebo.
Pirotta
Marie
M
Department of General Practice, University of Melbourne, 200 Berkeley Street, Carlton, Victoria, Australia, 3053. mpirotta@unimelb.edu.au
Gunn
Jane
J
Chondros
Patty
P
Grover
Sonia
S
Hurley
Susan
S
Garland
Suzanne
S
D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D002181:Candidiasis, Vulvovaginal / Q000209:etiology / Q000517:prevention & control*; D000529:Complementary Therapies; D005260:Female; D006801:Humans; D007778:Lactobacillus; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D012107:Research Design
D000900:Anti-Bacterial Agents